New combo therapy shows promise in shrinking head and neck tumors before surgery
NCT ID NCT06494189
First seen Jan 09, 2026 · Last updated May 21, 2026 · Updated 19 times
Summary
This early-phase study tested a new approach for people with head and neck cancer that can be removed by surgery. Before surgery, patients received low-dose radiation along with two drugs (tislelizumab and afatinib) to see if the combination is safe and tolerable. Only 9 patients took part, and the main goal was to find the safest radiation dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.